Can targeted drug cocktails tame mesothelioma?

NCT ID NCT03654833

NEW Completed Disease control Sponsor: University of Leicester Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial is testing several different targeted drug combinations in people with mesothelioma that has returned after initial treatment. The goal is to see which therapies can control the disease and potentially improve survival. Participants are assigned to a treatment based on the molecular profile of their tumor, aiming for a more personalized approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multiple targeted therapies: rucaparib, abemaciclib, pembrolizumab with bemcentinib, atezolizumab with bevacizumab, and dostarlimab with niraparib
What this could lead to: If successful, this trial could identify which targeted therapy works best for specific mesothelioma subtypes, leading to more personalized and effective treatment options.
What could go wrong: This is an early-phase trial, so the drugs may not work as hoped or may cause significant side effects. Results may not apply to all mesothelioma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESOTHELIOMA, MALIGNANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA, MALIGNANT

Contacts and locations

Locations

University Hospitals of Leicester NHS Trust

Leicester, LE1 5WW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.